Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 180

1.

Prevalence of and factors associated with depression among people living with HIV in France.

Feuillet P, Lert F, Tron L, Aubriere C, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)-VIH: Enquête sur les personnes atteintes (Vespa2) Study Group.

HIV Med. 2016 Sep 14. doi: 10.1111/hiv.12438. [Epub ahead of print]

PMID:
27625202
2.

VIH-25 - Évolution des caractéristiques des patients et des comorbidités dans une cohorte de personnes vivant avec le VIH, 2004-2014.

Bonnet F, Le Marec F, Leleux O, Cazanave C, Lazaro E, Duffau P, Vandenhende M, Mercié P, Neau D, Dabis F.

Med Mal Infect. 2016 Jun;46(4 Suppl 1):126. doi: 10.1016/S0399-077X(16)30570-4. French. No abstract available.

PMID:
27495706
3.

Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers.

Makinson A, Eymard-Duvernay S, Raffi F, Abgrall S, Bommart S, Zucman D, Valour F, Cheret A, Poizot-Martin I, Duvivier C, Mauboussin JM, Bonnet F, Tattevin P, Reynes J, Le Moing V; ANRS EP48 HIV CHEST study Team.

AIDS. 2016 Feb 20;30(4):573-82. doi: 10.1097/QAD.0000000000000943.

PMID:
26829006
4.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study.

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.

PMID:
26762990
5.

Sexual risk behaviour among people living with HIV according to the biomedical risk of transmission: results from the ANRS-VESPA2 survey.

Suzan-Monti M, Lorente N, Demoulin B, Marcellin F, Préau M, Dray-Spira R, Lert F, Spire B; ANRS-VESPA2 Study Group.

J Int AIDS Soc. 2016 Jan 8;19(1):20095. doi: 10.7448/IAS.19.1.20095. eCollection 2016.

6.

Risk Factors for HCV Reinfection or Transmission in HIV-HCV Coinfected MSM (ANRS-VESPA2 French National Survey).

Marcellin F, Demoulin B, Suzan-Monti M, Maradan G, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):e179-82. doi: 10.1097/QAI.0000000000000836. No abstract available.

PMID:
26569181
7.

Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients.

Duffau P, Wittkop L, Lazaro E, le Marec F, Cognet C, Blanco P, Moreau JF, Dauchy FA, Cazanave C, Vandenhende MA, Bonnet F, Thiebaut R, Pellegrin I; ANRS CO3 Aquitaine Cohort Study Group.

AIDS. 2015 Oct 23;29(16):2099-108. doi: 10.1097/QAD.0000000000000807.

PMID:
26544576
8.

Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).

Soulié C, Assoumou L, Darty M, Rodriguez C, Donati F, Sayon S, Peytavin G, Valantin MA, Caby F, Schneider L, Canestri A, Costagliola D, Katlama C, Calvez V, Marcelin AG; ROCnRAL ANRS-157 Study Group.

J Antimicrob Chemother. 2015 Dec;70(12):3339-44. doi: 10.1093/jac/dkv280. Epub 2015 Sep 22.

PMID:
26396157
9.

[Cough as the presenting feature of pulmonary AL amyloidosis: A case report].

Baulier G, Victor J, Mercié P, Lazaro E, Duffau P.

Rev Med Interne. 2016 May;37(5):363-6. doi: 10.1016/j.revmed.2015.08.008. Epub 2015 Sep 14. French.

PMID:
26383767
10.

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort.

PLoS One. 2015 Aug 6;10(8):e0134904. doi: 10.1371/journal.pone.0134904. eCollection 2015.

11.

Has the employment status of people living with HIV changed since the early 2000s?

Annequin M, Lert F, Spire B, Dray-Spira R; VESPA2 Study Group.

AIDS. 2015 Jul 31;29(12):1537-47. doi: 10.1097/QAD.0000000000000722.

PMID:
26244393
12.

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group.

HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28.

PMID:
26216031
13.

OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response.

Jacquemin C, Schmitt N, Contin-Bordes C, Liu Y, Narayanan P, Seneschal J, Maurouard T, Dougall D, Davizon ES, Dumortier H, Douchet I, Raffray L, Richez C, Lazaro E, Duffau P, Truchetet ME, Khoryati L, Mercié P, Couzi L, Merville P, Schaeverbeke T, Viallard JF, Pellegrin JL, Moreau JF, Muller S, Zurawski S, Coffman RL, Pascual V, Ueno H, Blanco P.

Immunity. 2015 Jun 16;42(6):1159-70. doi: 10.1016/j.immuni.2015.05.012. Epub 2015 Jun 9.

14.

Chest Low-Dose Computed Tomography for Early Lung Cancer Diagnosis as an Opportunity to Diagnose Vertebral Fractures in HIV-Infected Smokers, an ANRS EP48 HIV CHEST Substudy.

Thouvenin Y, Makinson A, Cournil A, Eymard-Duvernay S, Lentz P, Delemazure AS, Corneloup O, Fabre S, Quesnoy M, Poire S, Brillet PY, Cyteval C, Reynes J, Le Moing V; ANRS HIV CHEST Study Team.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):299-305. doi: 10.1097/QAI.0000000000000599.

PMID:
26058045
15.

Women living with HIV still lack highly effective contraception: results from the ANRS VESPA2 study, France, 2011.

Maraux B, Hamelin C, Bajos N, Dray-Spira R, Spire B, Lert F; Vespa2 study group.

Contraception. 2015 Aug;92(2):160-9. doi: 10.1016/j.contraception.2015.04.010. Epub 2015 May 2.

PMID:
25940932
16.

Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.

Lê MP, Soulié C, Assoumou L, Valantin MA, Duvivier C, Chas J, Ponscarme D, Marcelin AG, Calvez V, Katlama C, Peytavin G; ROCnRAL ANRS 157 Study Group.

J Antimicrob Chemother. 2015 Aug;70(8):2418-20. doi: 10.1093/jac/dkv113. Epub 2015 Apr 26. No abstract available.

17.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

18.

Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.

PMID:
25763785
19.

Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study).

Marcellin F, Demoulin B, Spire B, Suzan-Monti M, Roux P, Protopopescu C, Sagaon-Teyssier L, Duracinsky M, Dray-Spira R, Carrieri MP; ANRS-VESPA2 Study Group.

Expert Rev Gastroenterol Hepatol. 2015 May;9(5):701-13. doi: 10.1586/17474124.2015.1016914. Epub 2015 Feb 27.

PMID:
25723557
20.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk